The Immunogenicity of Therapeutic Proteins

Fiona Adair;Daniel Ozanne;

Publication

Article

February 15, 2002

BioPharm International

BioPharm International-02-01-2002

Volume15

Issue 2

Pages: 30-36

The Immunogenicity of Therapeutic Proteins

Author(s):

Fiona Adair,Daniel Ozanne

By Fiona Adair and Daniel Ozanne,Biovation Ltd., pp. 30-36. Immunogenicity is often a barrier to further development of potentially therapeutic proteins. That barrier often remains unknown until late in the development chain. The authors explore various strategies for preventing immunogenicity and for predicting it earlier in the process.

To view a PDF of this article from the BioPharm International archives, click this link

Articles in this issue

Using a Model and Tools to Standardize the Preparation for a Preapproval Inspection

Sale of Your Product Can Prevent Patenting: How to Avoid the On-Sale Bar

Outsourcing Outlook: Reaping the Benefits of E-Procurement

The Immunogenicity of Therapeutic Proteins

Analytical Advances: Calibration Management of Outsourced Calibrations

High-Throughput Biopharmaceutical Drug Development: Meeting the Coming Challenge

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!